Insmed | INSM - Cost Of Sales

Stock Price
155.80
Daily Change
-3.79 -2.37%
Monthly
11.76%
Yearly
127.21%
Q2 Forecast
157.54

Insmed reported $46.16M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Novartis USD 3.54B 7M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025